Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1627 1629 1764
This examiner grants 47% of resolved cases
Irina Neagu serves in Tech Center 1700 and Art Unit 1627. The examiner has 716 resolved cases. The allowance rate is 46.8 percent, which represents the frequency of grants for applications reaching a final resolution.
The interview lift is 57.3 percent. This 57.3 percent figure indicates that interviews correlate with an increased probability of allowance. When considering the 716 resolved cases, the 57.3 percent lift suggests that direct communication is a beneficial tactic for practitioners. The 46.8 percent baseline allowance rate is a key metric for evaluating the prosecution environment.
The median days to allowance is 1009. This 1009-day timeline reflects the duration for successful applications to reach a grant. The 1009-day figure provides a benchmark for expected pendency in Art Unit 1627. Practitioners can use this 1009-day median and the 716 resolved cases to inform their strategy and manage expectations for the timing of a final outcome.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18154498 | Alpha-Ketobutyrate, 2-Hydroxybutyrate, and Alpha-Ketoglutarate for Stimulating Hair Growth | Non-Final OA | The Regents of the University of California |
| 17786565 | COMPOSITION FOR THE TREATMENT OF AMYLOID-BETA ASSOCIATED DISEASES | Final Rejection | BASF SE |
| 18001889 | A NUTRITIONAL COMPOSITION COMPRISING 3-HYDROXYBUTYRIC ACID TO IMPROVE THE GASTROINTESTINAL BARRIER | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 18599953 | EFFICIENT STABILIZER IN CONTROLLING SELF ACCELERATED DECOMPOSITION TEMPERATURE OF PEROXYCARBOXYLIC ACID COMPOSITIONS WITH MINERAL ACIDS | Final Rejection | ECOLAB USA INC. |
| 18882674 | USE OF 2-HYDROXYBENZYLAMINE FOR THE TREATMENT OF SYSTEMIC LUPUS | Non-Final OA | Vanderbilt University |
| 16551594 | COMPOSITIONS AND METHODS FOR DELIVERING TETRAHYDROCANNABINOL AND KETONE BODIES | Final Rejection | AXCESS GLOBAL SCIENCES, LLC |
| 17790702 | Compositions and Methods for Treatment of Disease by Manipulation of Serine Metabolism | Non-Final OA | The Trustees of Princeton University |
| 17774838 | METHODS FOR THE TREATMENT OF DYSMYELINATING/DEMYELINATING DISEASES | Final Rejection | Board of Regents, The University of Texas System |
| 17773257 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTION | Final Rejection | UNIVERSITY OF SOUTH FLORIDA |
| 18694284 | COMPOUNDS AND METHODS FOR TREATING CANCERS THAT ARE MGMT DEFICIENT REGARDLESS OF MMR STATUS | Non-Final OA | Yale University |
| 18864351 | CRYSTALLINE POLYMORPHS OF N-METHYL-N-((1S,3S)-3-METHYL-3-((6-(1-METHYL-1H-PYRAZOL-4-YL)PYRAZOLO[1,5-A]PYRAZIN-4-YL)OXY)CYCLOBUTYL)ACRYLAMIDE | Non-Final OA | BIOGEN MA INC. |
| 18517049 | PHARMACOLOGICAL DEPLETION OF HEME FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME | Non-Final OA | THE SCRIPPS RESEARCH INSTITUTE |
| 18568243 | Treatment or Prevention of Ischaemia Reperfusion Injury | Final Rejection | Cambridge Enterprise Limited |
| 17625270 | Treatment of Heart Defects and Conditions in Pediatric Patients | Final Rejection | University of Pittsburgh - Of the Commonwealth System of Higher Education |
| 18947597 | USE OF PHOSPHOINOSITIDE 3-KINASE INHIBITORS FOR TREATMENT OF VASCULAR MALFORMATIONS | Non-Final OA | MEMORIAL SLOAN-KETTERING CANCER CENTER |
| 18119420 | ZWITTERIONIC COMPOUND, PRODUCING METHOD THEREOF, POLYMER THEREOF, AND CONDUCTIVE STRUCTURE | Non-Final OA | National Yang Ming Chiao Tung University |
| 16365074 | COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM | Final Rejection | IMBRIA PHARMACEUTICALS, INC. |
| 18338304 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | Final Rejection | Xygenyx Inc. |
| 17690680 | Methods and Compositions to Inhibit Symptoms Associated with Opioid Withdrawal | Final Rejection | SEN-JAM PHARMACEUTICAL LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy